Synergistic Anticancer Effects of Cell- free Culture Supernatant Derived from Lactobacillus sp. and Cisplatin on Human Breast and Ovarian Cancer Cells
Lactobacillus sp. 유래 무세포 배양상등액과 시스플라틴의 병용이 인체 유방암 및 난소암 세포에서 나타내는 시너지 항암 효과
- 주제(키워드) Lactobacillus cell-free supernatant(LCS) , Cisplatin , Triple-Negative Breast Cancer , High-Grade Serous Ovarian Cancer , Synergistic Anticancer effect
- 주제(DDC) 610.28
- 발행기관 아주대학교 일반대학원
- 지도교수 Mi Ran Kim
- 발행년도 2026
- 학위수여년월 2026. 2
- 학위명 석사
- 학과 및 전공 일반대학원 융합의과학과
- 실제URI http://www.dcollection.net/handler/ajou/000000035369
- 본문언어 영어
- 저작권 아주대학교 논문은 저작권에 의해 보호받습니다.
초록/요약
Synergistic Anticancer Effects of Cell-free Culture Supernatant Derived from Lactobacillus sp. and Cisplatin on Human Breast and Ovarian Cancer Cells Triple-negative breast cancer (TNBC; MDA-MB-231) and high-grade serous ovarian cancer (HGSOC; OVCAR-3 and OVCAR-4) are highly aggressive malignancies that remain major challenges in cancer therapy. TNBC is characterized by the absence of estrogen, progesterone, and HER2 receptors, while HGSOC is the most common and lethal subtype of epithelial ovarian cancer. Lactobacillus sp. culture supernatant (LCS), derived from the beneficial vaginal microbiota of healthy women, has been suggested to exert anticancer effects. This study aimed to investigate the synergistic anticancer activity of LCS in combination with cisplatin in MDA- MB-231 and OVCAR-3, OVCAR-4 cell lines. Lactobacillus strains were cultured in MRS broth at 37°C under anaerobic conditions for 24h. Following centrifugation (2,000g, 20 min) and 0.22 µm syringe filtration, cell-free culture supernatant (LCS) was obtained. To evaluate anticancer activity, MDA-MB-231, OVCAR-3, and OVCAR-4 cells were treated with the IC₇₀ concentrations of LCS and cisplatin, either alone or in combination. Anticancer effects were assessed by CCK-8 assay for cell viability, wound- healing assay for cell migration, RT-qPCR analysis of apoptosis-related markers (BAX/Bcl-2 ratio), and Annexin V-FITC/PI staining for apoptotic cell death. Co-treatment with LCS and cisplatin significantly reduced cancer cell viability compared with either treatment alone. Combination therapy markedly suppressed cell migration increased the BAX/Bcl-2 ratio and enhanced apoptotic cell death. These findings demonstrate that LCS potentiates the anticancer efficacy of cisplatin, suggesting its promise as an adjuvant therapeutic strategy. The combination of LCS and cisplatin exerted superior anticancer effects compared with monotherapy by promoting apoptosis and inhibiting migration in breast and ovarian cancer cells. These results indicate that LCS may enhance cisplatin efficacy and provide a potential combinatorial therapeutic approach for human breast and ovarian cancers. Key words: Lactobacillus cell-free supernatant (LCS), Cisplatin, Triple-Negative Breast Cancer, High-Grade Serous Ovarian Cancer, Synergistic Anticancer effect
more목차
Ⅰ. INTRODUCTION. 1
Ⅱ. MATERIALS AND METHODS. 4
1. Bacteria culture and preparation of cell-free culture supernatant 4
2. Cell culture 4
3. Cell viability assay 5
4. Interaction between LCS and Cisplatin. 6
5. Wound healing assay 7
6. RNA extraction and quantitative real-time PCR 7
7. Annexin V/PI assay 9
8. Statistical analysis 9
Ⅲ. RESULTS. 10
1. Lactobacillus sp. cell-free supernatant and cisplatin reduce human breast and ovarian cancer cell viability in a dose-dependent manner 10
2. Combined LCS and cisplatin treatment exerts synergistic effects 12
3. Combination treatment with LCS and cisplatin inhibits cancer cell migration 14
4. Apoptosis induction confirmed by ratio of BAX/Bcl-2 gene expression 17
5. Combination treatment induces apoptosis in breast and ovarian cancer cells 19
Ⅳ. DISCUSSION 22
Ⅴ. CONCLUSION 25
VI. REFERENCES 26
국문요약 29
